Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation.

Mendivil, Alberto A; Tung, Paul K; Bohart, Randy; Bechtol, Karen; Goldstein, Bram H

Mendivil, Alberto A; Tung, Paul K; Bohart, Randy; Bechtol, Karen; Goldstein, Bram H.

Afiliación

Mendivil AA; Gynecologic Oncology Associates, Newport Beach, CA 92663, United States.
Tung PK; University of California, Irvine, Department of Radiological Sciences, 1001 Health Sciences Road, Irvine, CA 92697-3950, United States.
Bohart R; Oso Home Care, 17175 Gillette Avenue, Irvine, CA 92614, United States.
Bechtol K; Gynecologic Oncology Associates, Newport Beach, CA 92663, United States.
Goldstein BH; Gynecologic Oncology Associates, Newport Beach, CA 92663, United States.

Gynecol Oncol Rep ; 26: 41-44, 2018 Nov.

Article en En | MEDLINE | ID: mdl-30246138

Palabras clave

BRAF mutation; Dabrafenib; Low grade serous ovarian cancer; Trametinib

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Gynecol Oncol Rep Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google